Sign in
CompletedPhase 1/2

Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
4 people enrolled
Started
9 Jun 2025
Ended
16 Jan 2026
Type of study
Interventional
Treatments tested
  • Esketamine (Intranasal Spray)
  • Massed Prolonged Exposure (PE)
Record updated
28 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Individual between the ages of 18-65 years old (Young adults [18 to 24 years old] must not be taking an antidepressant)
  • PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale (CAPS-5)
  • Able to speak and read English (due to standardization of outcome measures)
  • On stable doses of current medications for at least 4 weeks
  • Weigh between 50-100 kg (110-220 pounds)

Who cannot take part

  • Young adults (18-24) currently taking any antidepressant
  • Moderate or greater severity for alcohol or substance use disorder (DSM-5) in the previous six months
  • Current use (with past 4 weeks) of any prohibited concomitant medications
  • Benzodiazepines, other medications, sedatives, acute alcohol use, or recreational drug use that would put patients at risk in the judgment of clinical providers)
  • Lifetime history of psychotic disorder or history of significant psychotic symptoms
  • Lifetime history of manic episode
  • A history of ketamine or phencyclidine abuse
  • Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
  • Uncontrolled hypertension or tachycardia
  • A history of sensitivity or adverse reaction to ketamine or its excipients
  • An unstable medical, cardiovascular, pulmonary, or neurological condition that the investigator considers a contraindication to ketamine administration
  • Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation
  • Intracerebral hemorrhage
  • History of nasal surgery or nasal obstructions experienced as an adult
  • Evidence of a traumatic brain injury severe enough to interfere with comprehension and responding to the baseline screening questionnaires
  • Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index-Suicidality Subscale and corroborated by a clinical risk assessment by a credentialed provider)
  • Planned use of ketamine (i.e., for pain control) or participation in another trauma-focused psychotherapy during the time of the study
  • Pregnancy or breastfeeding; women of childbearing potential unwilling to utilize reliable methods of contraception
  • Inability to arrange for assisted transportation on ketamine treatment days due to recommendation that patient not drive for the remainder of the day following a ketamine treatment

Where in United States

  • The University of Texas Health Science Center at San AntonioSan Antonio, United States

About the trial

What the trial wants to find out

This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.

The group in the trial

  • Esketamine combined with Prolonged Exposure for PTSDTreatment being tested

    Esketamine (intranasal ketamine) will be administered 6 times over a 2-week period after administering PE sessions

    Treatment: Esketamine (Intranasal Spray) and Massed Prolonged Exposure (PE)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Combining Esketamine and Prolonged Exposure for PTSD: A Proof-of-Concept Clinical Trial
Record updated
28 January 2026